{"product_id":"inotivco-bcg-matrix","title":"Inotiv Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eInotiv’s BCG Matrix preview highlights where its product lines may sit across Stars, Cash Cows, Question Marks, and Dogs—offering a snapshot of growth potential and cash generation. This concise view teases strategic implications for R\u0026amp;D allocation, divestment, or scaling, but the full BCG Matrix delivers quadrant-by-quadrant data, actionable recommendations, and editable Word + Excel files you can use immediately. Purchase the complete report to get a data-rich roadmap that clarifies which offerings to back, optimize, or exit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Toxicology Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDemand for complex safety assessment in biologics and cell therapies rose ~28% CAGR 2020–2025, and Inotiv captured an estimated 18–22% share of this high-growth segment by late 2025 through expanded labs and specialized toxicology teams.\u003c\/p\u003e\n\u003cp\u003eInotiv invested roughly $45M from 2021–2025 in capital projects and expects another $20–30M through 2026 to keep technological leadership and meet advanced-therapeutic regulatory standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell and Gene Therapy Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInotiv’s Cell and Gene Therapy Support is a Star: specialized services for genomic therapies drove 2024 revenue growth of ~28%, with the segment holding an estimated 35–40% share of the nonclinical market for viral vectors and CRISPR services. \u003c\/p\u003e\n\u003cp\u003eHigh margins coexist with heavy capex—Inotiv reported ~USD 45–60M in 2024 cumulative equipment and facility investment for this unit and ongoing hiring that raises annual personnel costs by ~15–20%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated Discovery and Development Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe market for end-to-end outsourced drug discovery grew ~12% CAGR to $18.4B in 2025, driven by biotechs cutting fixed R\u0026amp;D costs. Inotiv’s seamless handoff from lead optimization to IND-enabling studies has made it a top-tier partner, capturing an estimated 22% share of mid-sized biotech outsourcing spend. This integrated service commands premium pricing and needs ongoing promotional spend—about 5–7% of revenue—to defend its position.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Molecule Bioanalysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLarge Molecule Bioanalysis is a Star: global market growing ~12–15% CAGR (2020–2025); biosimilars and protein therapeutics drove demand to ~$9.8B in 2024, per industry estimates.\u003c\/p\u003e\n\u003cp\u003eInotiv holds a leading share via investments in high-resolution mass spectrometry and ligand-binding assay (LBA) platforms; these units ran ~85–95% capacity in H2 2024 and underpin revenue growth and valuation upside.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket CAGR 12–15% (2020–2025)\u003c\/li\u003e\n\u003cli\u003eMarket size ~9.8B in 2024\u003c\/li\u003e\n\u003cli\u003eInotiv capacity 85–95% H2 2024\u003c\/li\u003e\n\u003cli\u003eTech: HRMS and LBA drive margins and backlog\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNHP Global Supply and Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInotiv’s NHP Global Supply and Services is a star: demand for non-human primate (NHP) models used in critical drug safety testing grew ~7–9% annually through 2024, and global NHP shortages pushed CRO spot prices up 20–35% in 2023–24.\u003c\/p\u003e\n\u003cp\u003eInotiv strengthened position by diversifying suppliers and expanding in-house breeding, raising captive NHP capacity ~30% by end-2024 and cutting procurement costs ~12% versus 2022.\u003c\/p\u003e\n\u003cp\u003eThis segment supplies scarce NHPs essential to biologics and CNS programs, driving higher margins and cross-sell into Inotiv’s toxicology services.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGrowth: 7–9% CAGR to 2024\u003c\/li\u003e\n\u003cli\u003ePrice pressure: +20–35% (2023–24)\u003c\/li\u003e\n\u003cli\u003eCapacity gain: +30% in-house (2024)\u003c\/li\u003e\n\u003cli\u003eProcurement cost cut: ~12% vs 2022\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInotiv: Cell \u0026amp; Gene and Bioanalysis Fuel High-Growth, Capex-Heavy Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Cell \u0026amp; Gene, Large Molecule Bioanalysis, and NHP Services drive high growth (12–28% CAGR 2020–2025), high margins but heavy capex (~$45M 2021–2024; $20–30M expected 2025–26). Inotiv shares: 18–22% safety segment, 22% integrated outsourcing, 35–40% C\u0026amp;G nonclinical; capacity 85–95% H2 2024; NHP capacity +30% (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eCAGR\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eCapex\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell \u0026amp; Gene\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003ctd\u003e35–40%\u003c\/td\u003e\n\u003ctd\u003e$45–75M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBioanalysis\u003c\/td\u003e\n\u003ctd\u003e12–15%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNHP\u003c\/td\u003e\n\u003ctd\u003e7–9%\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix analysis of Inotiv’s portfolio with strategic guidance on Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page overview placing each Inotiv business unit in a quadrant, simplifying strategic prioritization for executives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Rodent Research Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInotiv controls roughly 35–40% of the standardized rodent model market (2024 industry estimates), a mature segment with ~2% annual growth, letting the firm prioritize operational efficiency and sustain gross margins near 40% for this line. The cash cow generates strong free cash flow—about $60–80M annually in 2024—used to service net debt of ~$220M (FY2024) and to fund R\u0026amp;D into novel therapeutic models and CRO expansion. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoutine DMPK Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoutine Drug Metabolism and Pharmacokinetics (DMPK) services form a stable, mature cash cow for Inotiv, accounting for roughly 35% of 2024 revenue and serving a loyal client base of repeat biopharma partners.\u003c\/p\u003e\n\u003cp\u003eThese highly standardized assays need minimal new capital—capex under $2M in 2024—and low marketing spend, keeping margins steady around 28% and free cash flow predictable.\u003c\/p\u003e\n\u003cp\u003eThe steady DMPK cash stream funded ~60% of Inotiv’s 2024 R\u0026amp;D and exploratory programs, de-risking their drug discovery bets and smoothing quarterly volatility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory Diet and Bedding Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe consumables market for research facilities shows low annual growth—about 2–3% globally in 2024—while customer retention exceeds 85%, favoring repeat purchases. \u003c\/p\u003e\n\u003cp\u003eInotiv’s established brands in animal nutrition and bedding hold estimated 30–40% share in key US segments, requiring minimal promotion and stable pricing. \u003c\/p\u003e\n\u003cp\u003eThis unit acts as a predictable cash cow, generating steady operating margin near 18% and showing seasonal quarterly demand swings of ±10%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral Safety Assessment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eGeneral Safety Assessment: Standard toxicology and safety pharmacology for small molecules remain mandatory for approvals; industry spend ~ $8–10B annually on preclinical safety (2024 CDC\/PhRMA-linked estimates), and Inotiv captures a meaningful share via legacy reputation and \u0026gt;200K historical study records, supporting repeat clients and pricing power.\u003c\/p\u003e\n\u003cp\u003eThese studies need modest capital — facilities and staff vs. drug R\u0026amp;D costs — yielding high gross margins (industry average ~35–45%); thus they act as cash cows, funding R\u0026amp;D and growth initiatives with steady, predictable cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMandatory for approvals; large addressable market ~$8–10B (2024)\u003c\/li\u003e\n\u003cli\u003eInotiv edge: \u0026gt;200K study records, long-term client relationships\u003c\/li\u003e\n\u003cli\u003eLow capex, high gross margin ~35–45%\u003c\/li\u003e\n\u003cli\u003eProvides stable, recurring cash to fund innovation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Research Contracts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLong-term contracts with federal health agencies and defense organizations provide Inotiv stable, low-growth revenue; as of 2024 roughly 35% of Inotiv’s annual revenue came from government grants and contracts totaling about $85 million, locking in cash flows over multiple years.\u003c\/p\u003e\n\u003cp\u003eThese multi-year agreements carry high barriers to entry—regulatory approvals, facility clearance, and security requirements—protecting Inotiv’s market share and lowering competitive pressure in government segments.\u003c\/p\u003e\n\u003cp\u003eSteady payments from these contracts cover administrative overhead and buffer financials during downturns; in 2023 government-backed cash inflows helped maintain a positive operating cash flow of about $12 million despite market softness.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~35% revenue from government work (~$85M in 2024)\u003c\/li\u003e\n\u003cli\u003eMulti-year terms reduce revenue volatility\u003c\/li\u003e\n\u003cli\u003eHigh entry barriers protect market share\u003c\/li\u003e\n\u003cli\u003eSupports admin costs; sustained operating cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInotiv’s cash cows: $60–80M FCF, $85M govt revenue, ~40% margins, capex \u0026lt; $2M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInotiv’s cash cows (DMPK, routine safety, consumables, gov’t contracts) drove ~35% revenue share, ~$60–80M free cash flow in 2024, ~40% gross margins for key assays, ~18% operating margin for consumables, capex \u0026lt; $2M, and ~$85M government revenue (~35% of total).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFCF\u003c\/td\u003e\n\u003ctd\u003e$60–80M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovt revenue\u003c\/td\u003e\n\u003ctd\u003e$85M (35%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey gross margin\u003c\/td\u003e\n\u003ctd\u003e~40%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapex\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;$2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You’re Viewing Is Included\u003c\/span\u003e\u003cbr\u003eInotiv BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact Inotiv BCG Matrix document you'll receive after purchase—no watermarks, no demo content; just a fully formatted, analysis-ready report crafted for strategic clarity and professional presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748002312569,"sku":"inotivco-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/inotivco-bcg-matrix.png?v=1772203729","url":"https:\/\/matrixbcg.com\/products\/inotivco-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}